Evidence map›Paper›PMID 41356116›Full record

ArticleDiabetology international2026

Relationship between changes in uric acid levels and renal function during 12 months of treatment with luseogliflozin.

Takuma Izutsu, Hiroyuki Ito, Suzuko Matsumoto, Hideyuki Inoue, Shinichi Antoku, Toshiko Mori, Sugitatsu Yoshito, Hashimoto Yo, Hashimoto Tomoko, Sugawara Takashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takuma IzutsuDepartment of Diabetes and Endocrinology, Iwate Prefectural Central Hospital, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Moriokasi, Iwate 020-0066 Japan.ORCID 0009-0006-4747-0327
Hiroyuki ItoDepartment of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, 2-24-18 Higashikoiwa, Edogawa-ku, Tokyo-to, 133-0052 Japan.
Suzuko MatsumotoDepartment of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, 2-24-18 Higashikoiwa, Edogawa-ku, Tokyo-to, 133-0052 Japan.
Hideyuki InoueDepartment of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, 2-24-18 Higashikoiwa, Edogawa-ku, Tokyo-to, 133-0052 Japan.
Shinichi AntokuDepartment of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, 2-24-18 Higashikoiwa, Edogawa-ku, Tokyo-to, 133-0052 Japan.
Toshiko MoriDepartment of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, 2-24-18 Higashikoiwa, Edogawa-ku, Tokyo-to, 133-0052 Japan.
Sugitatsu YoshitoDepartment of Diabetes and Endocrinology, Iwate Prefectural Central Hospital, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Moriokasi, Iwate 020-0066 Japan.
Hashimoto YoDepartment of Diabetes and Endocrinology, Iwate Prefectural Central Hospital, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Moriokasi, Iwate 020-0066 Japan.
Hashimoto TomokoDepartment of Diabetes and Endocrinology, Iwate Prefectural Central Hospital, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Moriokasi, Iwate 020-0066 Japan.
Sugawara TakashiDepartment of Diabetes and Endocrinology, Iwate Prefectural Central Hospital, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Moriokasi, Iwate 020-0066 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors can effectively improve blood glucose levels in patients with type 2 diabetes, reduce the risk of cardiovascular disease and heart failure, and prevent chronic kidney disease. Although they reduce uric acid (UA) levels, few studies have investigated the relationship between UA reduction and renal function. We evaluated the degree of reduction in UA levels, various metabolic parameters, and renal function in patients with type 2 diabetes mellitus treated with luseogliflozin in order to develop a better renal protection strategy. Methods: This retrospective study analyzed 353 patients with type 2 diabetes who were newly treated with luseogliflozin. Patients were divided into two groups based on baseline UA levels, namely, the low group (< 6.0 mg/dL) and high group (≥ 6.0 mg/dL), with 74 patients in each group. Changes in metabolic parameters including glycated hemoglobin (HbA1c), UA levels, and estimated glomerular filtration rate (eGFR) were monitored over 12 months. Results: Both groups showed significant reductions in UA and HbA1c at 12 months. eGFR decreased significantly in the low group (- 3.1 ± 0.9 mL/min/1.73 m Conclusion: Changes in eGFR after luseogliflozin administration were significantly correlated with baseline eGFR, uACR, and changes in uric acid levels (Δ uric acid). The change in uric acid levels following SGLT2 inhibitor treatment was associated with metabolic parameters such as blood pressure and albuminuria, suggesting that it may function as a surrogate marker reflecting renal metabolic processes.

Indexed as

Estimated glomerular filtration rateLuseogliflozinRenal functionSodium glucose cotransporter 2 inhibitorsUric acid

Identifiers

PMID41356116
PMCPMC12675881

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.